YOLFTbeta
Avalo Therapeutics Inc

Avalo Therapeutics Inc

AVTX · NASDAQ · Healthcare / Biotechnology

7.76USD+0.06 (+0.78%)

Price History

Full chart

Market Stats

Previous Close7.70
Open7.73
Day Range7.45 – 7.94
52-Week Range12.41 – 24.27
Volume974.09K
Market Cap843.06M
P/E (TTM)0.00
Forward P/E0.00
EPS-4.41
Dividend Yield0.00%
Beta0.79
50-Day Avg18.53
200-Day Avg16.85

About

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Garry A. Neil M.D.
  • Employees33
  • Headquarters1500 Liberty Ridge Drive, Wayne, PA, United States, 19087, USA
  • Websitehttps://www.avalotx.com

Leadership

  • Dr. Garry A. Neil M.D.President, CEO & Director · b. 1954
  • Dr. Mittie Doyle FACR, M.D.Chief Medical Officer · b. 1965
  • Mr. Taylor BoydChief Business Officer · b. 1989
  • Dr. Solomon H. Snyder M.D.Founder and Chairman of Scientific Advisory Board · b. 1939
  • Dr. Barbara S. Slusher Ph.D.Founder and Member of Scientific Advisory Board · b. 1965
  • Mr. Christopher Ryan Sullivan CPACFO & Head of Investor relations · b. 1984
  • Mr. Paul C. Varki J.D., M.P.HChief Legal Officer · b. 1973
  • Ms. Ashley IvanowiczSenior Vice President of Human Resources
  • Dr. Dino C. Miano Ph.D.Senior Vice President of CMC & Technical Operations
  • Ms. Jennifer RileyChief Strategy Officer · b. 1975

Financials

Income Statement

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue82.76K---1.15M27.81M18.33M6.75M6.70M5.40M18.05M1.92M441.00K59.00K
Growth (%)-----+2312.24%-34.11%-63.17%-0.76%-19.42%+234.40%-89.34%-77.08%-86.62%
Cost of Revenue8.48M-9.50M23.51K8.24M635.65K7.48M-566.52K300.00K1.49M3.43M1.28M-366.00K344.00K
Gross Profit-8.39M--9.50M-23.51K-7.09M27.18M10.85M7.32M6.40M3.91M14.62M640.00K807.00K59.00K
Gross Margin-10142.39%----614.57%97.71%59.19%108.39%95.52%72.38%80.98%33.26%182.99%100.00%
Operating Expense2.10M-7.62M10.99M8.99M13.29M50.16M23.45M33.35M86.04M52.06M27.99M69.32M72.98M
Operating Income-10.49M-12.93M-17.12M-11.01M-16.08M13.89M-39.31M-16.14M-26.95M-82.13M-37.44M-27.35M-68.51M-72.92M
Operating Margin-12676.35%----1394.62%49.94%-214.52%-239.06%-402.34%-1521.56%-207.41%-1421.57%-15535.60%-123601.69%
EBITDA-10.48M-12.91M-17.09M-10.46M-16.05M14.35M-13.07M-13.51M-45.45M-80.50M-37.29M-23.29M-34.85M-77.75M
EBITDA Margin-12658.22%----1392.30%51.58%-71.32%-200.13%-678.47%-1491.24%-206.60%-1210.29%-7901.59%-131779.66%
Net Income-10.49M-13.05M-16.06M-10.49M-16.47M11.87M-40.05M-16.07M-63.50M-84.38M-41.66M-31.54M-35.13M-78.26M
Net Income Margin-12674.72%----1428.53%42.68%-218.55%-238.10%-947.90%-1563.10%-230.78%-1639.50%-7965.76%-132642.37%
R&D8.48M8.91M12.24M6.59M10.15M4.37M5.79M11.76M32.19M59.84M31.31M13.78M52.08M50.08M
R&D as % of Total Revenue10242.39%---880.31%15.72%31.57%174.27%480.56%1108.47%173.44%716.42%11809.07%84888.14%
Interest Expense-10.55K1.21M793.21K464.18K24.02K811.62K2.91M39.34M2.39M4.17M3.42M3.32M-
Interest Expense % of Total Revenue----40.26%0.09%4.43%43.06%587.25%44.29%23.10%177.60%752.15%-

Balance Sheet

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets10.02M5.08M12.32M21.66M5.77M43.12M70.25M36.11M43.76M80.21M33.37M20.99M150.73M116.46M
Total Liabilities1.54M22.92M38.65M8.57M5.56M15.26M49.34M15.11M19.19M57.13M44.28M13.69M17.70M33.41M
Total Equity8.48M-17.85M-26.33M13.08M207.00K27.86M20.91M21.00M24.56M23.08M-10.91M7.30M133.03M83.05M
Cash9.52M3.42M11.74M21.16M5.13M2.47M10.65M3.61M18.92M54.59M13.17M7.42M134.55M15.86M
Total Debt--7.21M5.56M2.35M-15.38M155.81K426.00K33.32M19.95M537.00K568.00K2.43M
Net Debt-9.52M-3.42M-4.53M-15.60M-2.77M-2.47M4.73M-3.45M-18.49M-21.27M6.78M-6.88M-133.98M-13.43M

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-9.29M-11.49M-15.52M-10.16M-14.57M12.52M-3.13M-19.13M-40.54M-70.89M-26.75M-30.68M-49.06M-51.46M
Investing Cash Flow-12.43K-29.27K-19.50K-19.98K-34.88K-18.91M865.46K-443.00K11.13M-113.00K-95.00K-133.00K356.00K-81.72M
Financing Cash Flow17.71M5.42M23.86M19.60M-1.43M3.74M10.40M12.56M44.78M106.76M-14.70M25.04M175.85M14.59M
Capital Expenditure12.43K29.27K19.50K19.98K34.88K23.32K564.41K262.01K63.00K113.00K95.00K158.00K00
Free Cash Flow-9.30M-11.51M-15.54M-10.18M-14.61M12.50M-3.69M-19.40M-40.60M-71.00M-26.85M-30.84M-49.06M-51.46M
Dividends Paid---1.37K---1.08M-32.90M14.81M---
FCF to OCF100.13%100.25%100.13%100.20%100.24%99.81%118.04%101.37%100.16%100.16%100.36%100.51%100.00%100.00%
Dividend Paid to FCF----0.01%----5.57%--46.33%-55.15%---

Earnings

Report DateNov 13, 2015Mar 23, 2016May 16, 2016Aug 15, 2016Nov 8, 2016Mar 14, 2017May 9, 2017Aug 14, 2017Nov 6, 2017Apr 2, 2018Aug 9, 2018Nov 13, 2018Mar 18, 2019May 9, 2019Aug 8, 2019Nov 14, 2019Mar 11, 2020May 7, 2020Aug 6, 2020Nov 9, 2020Mar 8, 2021May 13, 2021Aug 2, 2021Nov 9, 2021Mar 2, 2022May 5, 2022Aug 4, 2022Nov 7, 2022Mar 29, 2023May 4, 2023Aug 3, 2023Nov 9, 2023Mar 28, 2024May 13, 2024Aug 12, 2024Nov 7, 2024Mar 27, 2025May 12, 2025Aug 7, 2025Nov 6, 2025Mar 23, 2026May 13, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate--3.36-1123.19-1151.99-1411.19-1785.59-4.44-633.60-374.40-662.39-288.00-345.60-0.60-470.40-470.40-388.800.84-355.20-302.40-273.60-432.00-2.32-508.80-518.40-439.20-1.60-424.80-315.20-156.00-0.97-168.00-264.00-4.80-1.18-6.70-1.191.67-1.60-1.43-1.64-1.50-1.03-0.66-0.63
EPS Actual-0.08-6.36-1695.73-1203.83-1995.77-549.85-2.28-403.201497.59-316.80-547.20-2044.78-2.16-362.88-292.61-213.230.36-247.39-472.89-460.80-489.60-3.84-518.40-489.60-460.80-2.40-331.2081.60-249.60-0.85-141.60-26.40-116.21-141.004.210.98-2.74-1.25-1.92-2.19-0.37-0.98-0.83-
Surprise--89.29%-50.97%-4.50%-41.42%69.21%48.65%36.36%500.00%52.17%-90.00%-491.66%-260.00%22.86%37.80%45.16%-57.14%30.35%-56.38%-68.42%-13.33%-65.52%-1.89%5.56%-4.92%-50.00%22.03%125.89%-60.00%12.37%15.71%90.00%-2321.04%-11849.15%162.84%182.35%-264.56%21.88%-34.27%-33.54%75.25%4.85%-25.76%-
TimingAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap843.06M
Enterprise Value420.50M
Trailing P/E0.00
Forward P/E0.00
Price / Sales14289.21
Price / Book1.83
EPS-4.41
Book Value8.48
Revenue (TTM)59.00K
Gross Profit (TTM)-47.89M
EBITDA-91.25M
Profit Margin0.00%
Operating Margin-154847.45%
Return on Equity-36.27%
Return on Assets-18.50%
Shares Outstanding53.63M
Shares Float40.11M
Beta0.79
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 8 analystsTarget 44.08
  • Strong Buy
    6
  • Buy
    1
  • Hold
    1

Ownership Breakdown

Institutions
133.63%
Insiders
1.69%
Retail / Other
0.00%

Top Institutional Holders

  • Deep Track Capital, LP
    3.61M6.73%
  • Caligan Partners LP
    3.16M5.90%
  • TCG Crossover Management, LLC
    3.02M5.63%
  • Affinity Asset Advisors, LLC
    2.90M5.41%
  • FMR Inc
    2.88M5.37%
  • T. Rowe Price Investment Management,Inc.
    2.16M4.03%
  • Adage Capital Partners Gp LLC
    1.73M3.22%
  • Soleus Capital Management, L.P.
    1.65M3.09%
  • Bvf Inc
    1.63M3.04%
  • venBio Select Advisor LLC
    1.41M2.63%
  • Nantahala Capital Management, LLC
    1.24M2.30%
  • Logos Global Management LP
    1.15M2.14%
  • UBS Group AG
    1.14M2.13%
  • Point72 Asset Management, L.P.
    916.14K1.71%
  • Farallon Capital Management, L.L.C.
    916.00K1.71%
  • Trails Edge Capital Partners, LP
    891.88K1.66%

Top Fund Holders

  • State Street® SPDR® S&P® Biotech ETF
    2.14M3.99%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.68M3.12%
  • Fidelity Stock Selector Small Cap
    1.21M2.25%
  • iShares Russell 2000 ETF
    1.08M2.01%

Stock Splits

  • Dec 29, 20231:240
  • Jul 8, 20221:12